Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sensex, Nifty end lower amid weak global cues
The key equity indices ended marginally lower on Thursday as reports of possible RBI intervention to defend the rupee unnerved investors. Reports indicated that the Reserve Bank of India is considering a range of measures to stabilise the currency, including a rate hike, additional currency swaps and raising dollars from overseas investors. Persistent FII selling and profit booking at elevated valuations further weighed on sentiment, while weak global cues added to the pressure. The Nifty slipped below the 23,700 mark, dragged down by steep losses in IT and FMCG stocks.
Century Enka Q4 Results: Aditya Birla Group stock up 20% on multi-fold profit growth
Century Enka shares surged 20% after the Aditya Birla Group firm reported a sharp jump in fourth-quarter profit and margins, driven by a strong improvement in operating performance.
Buy, Sell Or Hold: Hitachi Energy, JK Tyre, Aditya Birla Capital, PNB, Maruti Suzuki, GAIL — Ask Profit
Buy Sell Hold
Sensex Today | Stock Market LIVE Updates: GIFT Nifty trades over 130 points higher; Jubilant Foodworks in focus
Sensex Today | Stock Market LIVE Updates: The bulls would hope for a replica of last night's rally on Wall Street, taking cues from some easing in bond yields and a fall in oil prices, even though nothing concrete has emerged from West Asia just yet. For the Nifty Bank, the 53,000 - 54,000 range remains, even as the index remains choppy.
Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd Bank
Markets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downside. Several companies like ITC, Nykaa, and IndusInd Bank are in focus due to Q4 results and news developments, including Lenskart's profit decline and Dr. Reddy's new diabetes drug launch.
Stocks to Watch for May 21: Aditya Birla Capital, Dr Reddy's Lab, Jubilant Food, Bosch India and more
From Dr Reddy's Laboratories announcing the launch of its oral semaglutide biosimilar in India under the brand name Obeda to Whirlpool of India Ltd reporting a 32.7% year-on-year decline in net profit Q4, here are some stocks to track ahead of Thursday trading session.
Aditya Birla Grp to invest Rs 3,080 cr in fin services arm, IFC to pump Rs 920 cr
Aditya Birla Capital is raising Rs 4,000 crore for future growth. The Aditya Birla Group will invest Rs 3,080 crore and IFC will invest Rs 980 crore. This capital infusion will fund growth objectives, including lending and investments. The company aims to expand access to financing for entrepreneurs and businesses. This move supports India's economic transformation and financial inclusion.
Aditya Birla Capital Approves Rs 4,000-Cr Share Issuance; Promoter Grasim Leads Infusion
Aditya Birla Capital plans to raise Rs 2,880 crore from promoter Grasim Industries.
Aditya Birla Capital raises ₹4,000 crore to fund growth, confirms CNBC-TV18 Newsbreak
The company said the proceeds from the issue will be used for growth objectives, augmentation of the capital base, funding requirements for the lending business and general corporate purposes, including investments in subsidiaries, joint ventures and associates.
Hindalco share price jumps 4% after Novelis posts Q4 earnings 2026; check results date for the Aditya Birla Group stock
Hindalco Industries shares rose 4% to ₹1,089.60 after Novelis reported a quarterly net loss of $84 million. Despite fire-related impacts, quarterly net sales increased 4% to $4.8 billion, driven by higher aluminium prices.
Sensex Rejig: Trent likely exclusion; Could be replaced by either of these two names
Two names remain the key contenders to replace Trent in the Sensex as part of the rejig. One is Aditya Birla Group's Hindalco Industries, and the other is Shriram Finance.
Vodafone Idea’s survival has certainty, but shareholders’ patience may be tested
Vodafone Idea reduced its loss before tax by 13% to ₹5,515 crore in Q4FY26. The Aditya Birla Group will infuse ₹4,730 crore into the company. Despite this, investor concerns remain over Vodafone’s ability to grow amid high competition and significant debt.